Wilbanks Smith & Thomas Asset Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $11.4M | Sell |
14,613
-141
| -1% | -$100K | 0.32% | 80 |
|
|
2023
Q4 | $8.6M | Sell |
14,754
-32
| -0.2% | -$18.7K | 0.26% | 86 |
|
|
2023
Q3 | $7.94M | Sell |
14,786
-584
| -4% | -$301K | 0.27% | 83 |
|
|
2023
Q2 | $7.21M | Buy |
15,370
+1,032
| +7% | +$433K | 0.24% | 89 |
|
|
2023
Q1 | $4.92M | Sell |
14,338
-176
| -1% | -$59.4K | 0.17% | 101 |
|
|
2022
Q4 | $5.31M | Buy |
14,514
+486
| +3% | +$172K | 0.2% | 95 |
|
|
2022
Q3 | $4.54M | Buy |
14,028
+138
| +1% | +$43.7K | 0.19% | 95 |
|
|
2022
Q2 | $4.5M | Buy |
13,890
+876
| +7% | +$263K | 0.19% | 98 |
|
|
2022
Q1 | $3.75M | Sell |
13,014
-133
| -1% | -$34.2K | 0.15% | 112 |
|
|
2021
Q4 | $3.63M | Sell |
13,147
-238
| -2% | -$60.3K | 0.13% | 126 |
|
|
2021
Q3 | $3.09M | Sell |
13,385
-410
| -3% | -$101K | 0.12% | 128 |
|
|
2021
Q2 | $3.17M | Sell |
13,795
-160
| -1% | -$32.1K | 0.12% | 129 |
|
|
2021
Q1 | $2.61M | Buy |
13,955
+118
| +0.9% | +$23.1K | 0.11% | 136 |
|
|
2020
Q4 | $2.34M | Sell |
13,837
-625
| -4% | -$93.3K | 0.11% | 131 |
|
|
2020
Q3 | $2.14M | Sell |
14,462
-89
| -0.6% | -$13.8K | 0.12% | 126 |
|
|
2020
Q2 | $2.39M | Buy |
14,551
+147
| +1% | +$22.6K | 0.15% | 112 |
|
|
2020
Q1 | $2M | Buy |
14,404
+123
| +0.9% | +$16.9K | 0.15% | 111 |
|
|
2019
Q4 | $1.88M | Buy |
14,281
+9
| +0.1% | +$1.04K | 0.11% | 131 |
|
|
2019
Q3 | $1.6M | Buy |
14,272
+396
| +3% | +$44.1K | 0.1% | 139 |
|
|
2019
Q2 | $1.54M | Sell |
13,876
-6,848
| -33% | -$806K | 0.1% | 141 |
|
|
2019
Q1 | $2.69M | Sell |
20,724
-499
| -2% | -$60.7K | 0.17% | 116 |
|
|
2018
Q4 | $2.46M | Buy |
21,223
+388
| +2% | +$43.3K | 0.17% | 98 |
|
|
2018
Q3 | $2.24M | Buy |
20,835
+12,695
| +156% | +$1.27M | 0.14% | 118 |
|
|
2018
Q2 | $695K | Buy |
8,140
+234
| +3% | +$19.2K | 0.06% | 163 |
|
|
2018
Q1 | $612K | Buy |
7,906
+2,839
| +56% | +$229K | 0.05% | 170 |
|
|
2017
Q4 | $428K | Hold |
5,067
| – | – | 0.03% | 214 |
|
|
2017
Q3 | $433K | Hold |
5,067
| – | – | 0.04% | 207 |
|
|
2017
Q2 | $417K | Hold |
5,067
| – | – | 0.04% | 200 |
|
|
2017
Q1 | $426K | Buy |
5,067
+195
| +4% | +$15.6K | 0.04% | 189 |
|
|
2016
Q4 | $358K | Sell |
4,872
-775
| -14% | -$57.7K | 0.03% | 198 |
|
|
2016
Q3 | $453K | Sell |
5,647
-51
| -0.9% | -$4.08K | 0.04% | 172 |
|
|
2016
Q2 | $449K | Buy |
5,698
+825
| +17% | +$62.1K | 0.05% | 175 |
|
|
2016
Q1 | $351K | Sell |
4,873
-322
| -6% | -$24.4K | 0.04% | 201 |
|
|
2015
Q4 | $438K | Buy |
5,195
+82
| +2% | +$6.8K | 0.04% | 171 |
|
|
2015
Q3 | $428K | Sell |
5,113
-1,194
| -19% | -$101K | 0.06% | 162 |
|
|
2015
Q2 | $527K | Buy |
6,307
+76
| +1% | +$5.79K | 0.05% | 173 |
|
|
2015
Q1 | $453K | Hold |
6,231
| – | – | 0.04% | 177 |
|
|
2014
Q4 | $430K | Buy |
6,231
+1,702
| +38% | +$115K | 0.04% | 190 |
|
|
2014
Q3 | $294K | Buy |
4,529
+105
| +2% | +$6.65K | 0.03% | 216 |
|
|
2014
Q2 | $275K | Buy |
4,424
+9
| +0.2% | +$537 | 0.03% | 232 |
|
|
2014
Q1 | $260K | Sell |
4,415
-90
| -2% | -$5.02K | 0.03% | 237 |
|
|
2013
Q4 | $230K | Buy |
4,505
+95
| +2% | +$4.76K | 0.03% | 246 |
|
|
2013
Q3 | $222K | Sell |
4,410
-298
| -6% | -$15.6K | 0.03% | 247 |
|
|
2013
Q2 | $231K | Buy |
+4,708
| New | +$256K | 0.04% | 226 |
|
Other funds holding LLY
Wilbanks Smith & Thomas Asset Management's LLY Position: Q1 2024 in Review
Wilbanks Smith & Thomas Asset Management reduced its Eli Lilly (LLY) stake by 0.96% in Q1 2024, selling an estimated $100K and leaving 14,613 shares worth $11.4M. The position accounts for 0.32% of the portfolio, ranked #80.
Wilbanks Smith & Thomas Asset Management first reported a position in LLY in Q2 2013 and has held it in 44 quarters since. 3,461 funds tracked by Wall St. Rank hold LLY as of Q1 2024.
- Wilbanks Smith & Thomas Asset Management held 14,613 shares of Eli Lilly worth $11.4M as of Q1 2024.
- Wilbanks Smith & Thomas Asset Management sold 141 Eli Lilly shares in Q1 2024, an estimated $100K.
- Eli Lilly made up 0.32% of Wilbanks Smith & Thomas Asset Management's portfolio in Q1 2024, its #80 holding.
- Wilbanks Smith & Thomas Asset Management first reported a position in Eli Lilly in Q2 2013 and has held it in 44 quarters since.
- 3,461 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2024.
Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q1 2024, filed 7 May 2024.